Two cases of pure red-cell aplasia due to anti-erythropoietin antibodies

Journal of Nephrology

Volumn 18, Issue 1, 2005, Pages 102-105

  Yang, Jaeseok ^a   Joo, Kwon Wook ^a,b   Kim, Yon Su ^a   Ahn, Curie ^a   Han, Jin Suk ^a   Kim, Suhnggwon ^a   Lee, Jung Sang ^a  

^a Seoul National University   (South Korea)

^b NONE   (South Korea)

Author keywords

Anti erythropoietin antibodies; Pure red cell aplasia

Indexed keywords

CORTICOSTEROID; EPOKINE; EPORON; ERYTHROPOIETIN; ESPOGEN; IMMUNOGLOBULIN; OXYMETHOLONE; PREDNISOLONE; PROTEIN ANTIBODY; RECOMBINANT ERYTHROPOIETIN; ANTIBODY;

ADULT; ANEMIA; ANTIBODY DETECTION; ARTICLE; ASIAN; BIOASSAY; CASE REPORT; CAUCASIAN; COLONY FORMATION; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DRUG RESPONSE; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROID CELL; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INJECTION SITE REACTION; KOREA; MALE; PRURITUS; PURE RED CELL ANEMIA; RADIOIMMUNOPRECIPITATION; THROMBOCYTOPENIA; URTICARIA; DRUG HYPERSENSITIVITY; IMMUNOLOGY; SKIN DISEASE;

ADULT; ANEMIA; ANTIBODIES; DRUG HYPERSENSITIVITY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; RED-CELL APLASIA, PURE; SKIN DISEASES;

EID: 16844369036     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (suppl 1): S1-266.
2. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-9.
3. Sokol L, Prchal JT. Pure red cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
4. Weber G, Gross J, Kromminga A, Loew HH, Eckardt KU. Allergic skin and systemic reactions in a patient with pure red cell aplasia and anti-erythropoietin antibodies challenged with different epoetins. J Am Soc Nephrol 2002; 13: 2381-3.
5. Casadevall N. Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002; 17 (suppl 5): S42-7.
6. Casadevall N, Nataf J, Viron B, Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P, Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-75.
7. Rosset J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004; 15: 398-406.
8. Castelli G, Famularo A, Semino C, Machi AM, Ceci A, Cannella G, Melioli G. Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 2000; 41: 313-8.
9. Chng WJ, Tan LK, Liu TC. Cyclosporine treatment for patients with CRF who developed pure red blood cell aplasia following EPO therapy. Am J Kidney Dis 2003; 41: 692-5.
10. Tanuma Y, Yokoo A, Takashima H. Acquired pure red cell aplasia in a hemodialyzed patient. Int J Urol 2003; 10: 550-3.
11. Duffield J, Mann S, Horn L, Winney R. Low-dose cyclosporin therapy for recombinant erythropoietin-induced pure red-cell aplasia. Nephrol Dial Transplant 2004; 19: 479-81.
12. Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991; 28: 275-84.
13. Beguin Y. Erythropoietin and platelet production. Haematologica 1999; 84: 541-7.